Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

What Was Tested

The paper reports a study of Glucagon and Lixisenatide, published as a randomized controlled trial.

Who Took Part

The abstract describes 542 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

Some patients received a placebo instead of Glucagon, giving a reference point.

The Glucagon group and the comparison group ran side by side rather than switching.

The primary end-point was change in HbA(1c) from baseline to 13 weeks in the intent-to-treat population.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Drug Resistance, Glucagon-Like Peptide-1 Receptor, Glycated Hemoglobin, Hypoglycemic Agents and Metformin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon and Lixisenatide in 542 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Glucagon compound page and the Lixisenatide compound page.